Shares of OPKO Health, Inc. (NASDAQ:OPK – Get Free Report) have been given a consensus recommendation of “Hold” by the six research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $1.55.
OPK has been the subject of several recent research reports. Wall Street Zen cut OPKO Health from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Barrington Research lowered shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. Finally, Weiss Ratings raised shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th.
Institutional Investors Weigh In On OPKO Health
OPKO Health Trading Up 2.1%
Shares of NASDAQ OPK opened at $1.46 on Friday. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -5.41 and a beta of 1.42. The business has a 50 day simple moving average of $1.18 and a 200 day simple moving average of $1.24. OPKO Health has a 52 week low of $0.98 and a 52 week high of $1.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.17 and a current ratio of 3.61.
OPKO Health (NASDAQ:OPK – Get Free Report) last announced its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $124.20 million during the quarter, compared to analysts’ expectations of $130.51 million. OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.The firm’s quarterly revenue was down 17.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.10) EPS. On average, research analysts predict that OPKO Health will post -0.29 earnings per share for the current fiscal year.
About OPKO Health
OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.
In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.
Read More
- Five stocks we like better than OPKO Health
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
